XT
DNLI icon

XTX Topco’s Denali Therapeutics DNLI Stock Holding History

XTX Topco’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.84M Buy
226,953
+148,386
+189% +$3.05M 0.08% 317
2026
Q1 		$1.51M Buy
+78,567
New +$1.56M 0.03% 1076
2025
Q4 		– Sell
-65,345
Closed -$949K – 3410
2025
Q3 		$949K Buy
+65,345
New +$939K 0.05% 614
2025
Q2 		– Sell
-13,485
Closed -$183K – 2537
2025
Q1 		$183K Sell
13,485
-2,602
-16% -$49.9K 0.01% 1723
2024
Q4 		$328K Buy
+16,087
New +$412K 0.03% 1142
2023
Q4 		– Sell
-44,656
Closed -$921K – 1706
2023
Q3 		$921K Buy
+44,656
New +$1.13M 0.16% 118
2023
Q1 		– Sell
-12,231
Closed -$340K – 1365
2022
Q4 		$340K Buy
12,231
+208
+2% +$6.19K 0.07% 508
2022
Q3 		$369K Buy
+12,023
New +$391K 0.09% 378
2021
Q2 		– Sell
-3,683
Closed -$210K – 865
2021
Q1 		$210K Buy
+3,683
New +$247K 0.1% 475

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

XTX Topco's DNLI Position: Q2 2026 in Review

XTX Topco increased its Denali Therapeutics (DNLI) stake by 189% in Q2 2026, buying an estimated $3.05M and bringing the position to 226,953 shares worth $5.84M. The position accounts for 0.08% of the portfolio, ranked #317.

XTX Topco first reported a position in DNLI in Q1 2021 and has held it in 9 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • XTX Topco held 226,953 shares of Denali Therapeutics worth $5.84M as of Q2 2026.
  • XTX Topco bought 148,386 Denali Therapeutics shares in Q2 2026, an estimated $3.05M.
  • Denali Therapeutics made up 0.08% of XTX Topco's portfolio in Q2 2026, its #317 holding.
  • XTX Topco first reported a position in Denali Therapeutics in Q1 2021 and has held it in 9 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.